The study is a double-blind, placebo-controlled, exploratory randomized clinical trial to assess the safety and efficacy of IFB-088 plus riluzole 100 mg, vs placebo plus riluzole 100 mg in patients with bulbar-onset ALS.
Nantes, France--(Newsfile Corp. - January 10, 2022) - InFlectis BioScience SAS, a clinical-stage company developing innovative therapeutics for neuromuscular diseases by harnessing the Integrated Stress Response (ISR), receives approval from the French Regulatory Authority ANSM to start a Phase 2 clinical trial evaluating IFB-088 for the treatment of Amyotrophic Lateral Sclerosis (ALS). The study is a double-blind, placebo-controlled, exploratory randomized clinical trial to assess the safety and efficacy of IFB-088 plus riluzole 100 mg, vs placebo plus riluzole 100 mg in patients with bulbar-onset ALS.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- ANSM approves Phase 2 clinical trial for IFB-088 in France.
- The study is a double-blind, placebo-controlled, exploratory randomized clinical trial to assess the safety and efficacy of IFB-088.
- Patients with bulbar-onset ALS will receive IFB-088 in combination with riluzole, or placebo plus riluzole.
Click image above to view full announcement.
About InFlectis
InFlectis BioScience is a France-based clinical stage company developing first-in-class therapies for neuromuscular diseases. The company is in clinical development with an orally available small molecule — IFB-088 — that has the potential to extend lives or improve the quality-of-life for people with from amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT) — two rare progressive nerve conditions. InFlectis designs therapies to boost a cellular command center — the Integrated Stress Response — that ensures healthy levels of proteins and protein structures. Excessive and prolonged cellular stress can overwhelm this command center, resulting in the loss of functional cells and onset or progression of neuromuscular diseases. InFlectis’ drug candidates keep this command center operating to prevent downstream effects that lead to disease.
Contacts:
Philippe Guédat
philippeguedat@inflectisbioscience.com
Pierre Miniou
pierreminiou@inflectisbioscience.com
Francina Agosti, Ph.D.
francina@octaviant.com
Source: Inflectis
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/109537
